PD40-11 CLINICAL ACTIVITY OF NIVOLUMAB IN ADVANCED HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER (HLRCC)-ASSOCIATED KIDNEY CANCER (2021)

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) II (PD40)1 Sep 2021PD40-11 CLINICAL ACTIVITY OF NIVOLUMAB IN ADVANCED HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER (HLRCC)-ASSOCIATED KIDNEY CANCER Alexis Rompre-Brodeur, Julia Friend, Daniel Girardi, Sandeep Gurram, Paul D. Leger, Munjid Al-Harthy, Ashkan Malayeri, Beatriz Walter Rodriguez, Rabindra Gautam, Jeanny B. Aragon-Ching, Jaime R. Merchan, Arash Rezazadeh Kalebasty, Maria J Merino, W Marston Linehan, and Ramaprasad Srinivasan Alexis Rompre-BrodeurAlexis Rompre-Brodeur More articles by this author , Julia FriendJulia Friend More articles by this author , Daniel GirardiDaniel Girardi More articles by this author , Sandeep GurramSandeep Gurram More articles by this author , Paul D. LegerPaul D. Leger More articles by this author , Munjid Al-HarthyMunjid Al-Harthy More articles by this author , Ashkan MalayeriAshkan Malayeri More articles by this author , Beatriz Walter RodriguezBeatriz Walter Rodriguez More articles by this author , Rabindra GautamRabindra Gautam More articles by this author , Jeanny B. Aragon-ChingJeanny B. Aragon-Ching More articles by this author , Jaime R. MerchanJaime R. Merchan More articles by this author , Arash Rezazadeh KalebastyArash Rezazadeh Kalebasty More articles by this author , Maria J MerinoMaria J Merino More articles by this author , W Marston LinehanW Marston Linehan More articles by this author , and Ramaprasad SrinivasanRamaprasad Srinivasan More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002050.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is a hereditary condition characterized by an increased risk for a clinically aggressive papillary renal cell cancer variant. We aimed to evaluate the clinical activity of nivolumab (anti-PD1 antibody) in patients with advanced HLRCC-associated kidney cancer as salvage therapy following treatment with antiangiogenic targeted therapy. METHODS: Patients with advanced HLRCC-associated kidney cancer who were followed at our institution and had received nivolumab between 2016 and 2020 were reviewed. Objective response rate, progression-free survival (PFS), and duration of response (DOR) per RECIST 1.1 were evaluated. RESULTS: Twenty patients with advanced HLRCC-associated kidney cancer (median age 48.9 years; 16 males/4 females) were identified for inclusion in this analysis. All had received prior antiangiogenic therapy (bevacizumab in combination with erlotinib in 18/20 [90%]). 13/20 (65%) had received one prior line of treatment and 7/20 (35%) had received two or three lines of treatment. The most common sites of metastasis were retroperitoneal (50%), mediastinal lymph nodes (30%), bones (30%), and liver (30%). Seven patients (35%) achieved an objective response including four (20%) with a complete response and three (15%) with a partial response. Median follow up was 22.7 months, and the median PFS was 4.2 months (95% CI 3.4-NR). In patients with an objective response, the median DOR was of 25.7 months (95% CI 18.9-NR). Thirteen patients (65%) were alive at the time of data cutoff and the median OS was not reached (95% CI 21.7-NR). Therapy was generally well tolerated, but two patients (10%) discontinued therapy for immune-related adverse events. CONCLUSIONS: Nivolumab demonstrated antitumor activity with acceptable toxicity in patients with advanced HLRCC-associated kidney cancer treated with prior antiangiogenic therapy. To our knowledge, this report represents the first systematic evaluation of the efficacy of an immune checkpoint inhibitor in this patient population. Source of Funding: NA © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e678-e678 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Alexis Rompre-Brodeur More articles by this author Julia Friend More articles by this author Daniel Girardi More articles by this author Sandeep Gurram More articles by this author Paul D. Leger More articles by this author Munjid Al-Harthy More articles by this author Ashkan Malayeri More articles by this author Beatriz Walter Rodriguez More articles by this author Rabindra Gautam More articles by this author Jeanny B. Aragon-Ching More articles by this author Jaime R. Merchan More articles by this author Arash Rezazadeh Kalebasty More articles by this author Maria J Merino More articles by this author W Marston Linehan More articles by this author Ramaprasad Srinivasan More articles by this author Expand All Advertisement PDF downloadLoading ...